5,6-二甲氧基-2,3-二氢-1H-茚-2-胺 | 83598-55-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 5,6-二甲氧基-2,3-二氢-1H-茚-2-胺
• 英文名称: 5,6-dimethoxy-2-aminoindan
• 英文别名: 5,6-Dimethoxy-2-indanylamine；5,6-dimethoxy-2,3-dihydro-1H-inden-2-amine
• CAS: 83598-55-4
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: TZASGTHDRXFGHT-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C (decomp)
• 沸点：
  309.5±42.0 °C(Predicted)
• 密度：
  1.109±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  5,6-二甲氧基-2,3-二氢-1H-茚-2-胺 在 palladium on activated charcoal 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 5,6-dimethoxy-2-(sulfamoylamino)-2,3-dihydro-1H-indene
  参考文献：
  名称：

  Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors

  摘要：

  Sulfamides represent an important class of biologically active compounds. A series of novel sulfamides were synthesized from 1-aminoindanes, 1-aminotetralin, 2-aminoindanes and 2-aminotetralin via the reactions of free amines, benzyl alcohol and chlorosulfonyl isocyanate (CSI) followed by hydrogenolysis of the obtained sulfamoylcarbamates. Carbonic anhydrase (CA, EC 4.2.1.1) inhibitory effects of the new sulfamides have been investigated. The human (h) isozymes hCA I and hCA II have been investigated in this study by using an esterase assay with 4-nitrophenyl acetate as substrate. The new sulfamides showed inhibition constants in the micro-submicromolar range, with one compound (N-(indane-1-yl) sulfamide) showing a K-i of 0.45 mu M against hCA I and of 1.07 mu M against hCA II. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.019
• 作为产物：
  描述：

  3-(3,4-dimethoxy-phenyl)-propionyl chloride 在 10percent Pd/C 盐酸 、 三氯化铝 、 亚硝酸丁酯 、 硫酸 、 氢气 作用下， 以 甲醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 20.0~40.0 ℃ 、344.75 kPa 条件下， 反应 10.5h， 生成 5,6-二甲氧基-2,3-二氢-1H-茚-2-胺
  参考文献：
  名称：

  Dopamine D₃ Receptor Antagonists. 1. Synthesis and Structure−Activity Relationships of 5,6-Dimethoxy-N-alkyl- and N-Alkylaryl-Substituted 2-Aminoindans

  摘要：

  5,6-Dimethoxy-2-(N-dipropyl)-aminoindan (3, PNU-99194A) was found to be a selective dopamine D-3 receptor antagonist with potential antipsychotic properties in animal models. To investigate the effects of nitrogen substitution on structure-activity relationships, a series of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans were synthesized and evaluated in vitro for binding affinity and metabolic stability. The results indicate that substitution at the amine nitrogen of the 2-aminoindans is fairly limited to the di-N-propyl group in order to achieve selective D-3 antagonists. Thus, combinations of various alkyl groups were generally inactive at the D-3 receptor. Although substitution with an N-alkylaryl or N-alkylheteroaryl group yields compounds with potent D-3 binding affinity, the D-2 affinity is also enhanced, resulting in a less than 4-fold preference for the D-3 receptor site, and no improvements in metabolic stability were noted. A large-scale synthesis of the D-3 antagonist 3 has been developed that has proven to be reproducible with few purification steps. The improvements include the use of 3,4-dimethoxybenzaldehyde as a low-cost starting material to provide the desired 5,6-dimethoxy-1-indanone 5c in good overall yield (65%) and the formation of a soluble silyl oxime 17 that was reduced efficiently with BH3. Me2S. The resulting amino alcohol was alkylated and then deoxygenated using a Lewis acid and Et3SiH to give the desired product 3 in good overall yield of (similar to 65%) from the indanone 5c.

  DOI：

  10.1021/jm010145w

文献信息

• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
  申请人：Diaz Caroline Jean

  公开号：US20100222345A1

  公开（公告）日：2010-09-02

  This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

  这项发明涉及新型化合物，它们是阿片受体的拮抗剂或逆向激动剂之一，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗中的应用。
• METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
  申请人：IGNAR DIANE MICHELE

  公开号：US20100113512A1

  公开（公告）日：2010-05-06

  A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

  使用含有新型阿片受体拮抗剂或反向激动剂的药物组合物治疗暴食症、厌食症、暴食症、过度药物或酒精使用或其他未明确指定的进食障碍的治疗方法。
• NOVEL HETEROCYCLE COMPOUNDS
  申请人：Barvian Kevin Karl

  公开号：US20090054431A1

  公开（公告）日：2009-02-26

  The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.

  本发明涉及一种新型化合物，该化合物是阿片受体的拮抗剂或反向激动剂。这些化合物在治疗哺乳动物，特别是人类的肥胖和相关疾病和/或症状中是有用的。还公开了制备和使用这些化合物的方法。
• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
  申请人：Cowan David John

  公开号：US20110124559A1

  公开（公告）日：2011-05-26

  Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

  小说化合物，它们是阿片受体的拮抗剂或逆向激动剂，含有它们的药物组合物，以及它们的制备方法。
• 一种2-氨基茚满衍生物的合成方法及其产品
  申请人：龙曦宁（上海）医药科技有限公司

  公开号：CN105884626B

  公开（公告）日：2017-10-20

  本发明提供了一种2‑氨基茚满衍生物的合成方法，即以5,6二取代1‑茚酮为起始原料，先进行溴化反应，再进行盖布瑞尔反应，接着加入水合肼，进行水解反应同时生成腙，最后在高沸点溶剂中加入强碱进行加热水解，制得目标产物2‑氨基茚满衍生物。本发明还提供了由上述合成方法制得的2‑氨基茚满衍生物。与现有技术中的2‑氨基茚满衍生物合成方法相比，本发明所提供的合成方法反应原料廉价，反应条件温和，反应步骤简单，易于操作，并且所得产品的收率较高，适于工业化生产，因此，具有很好的应用前景与市场潜力。